Duopharma to proceed with niche products


Some Duopharma products

KUALA LUMPUR: Duopharma Biotech Bhd, which recorded stronger earnings in the third quarter ended Sept 30, will push ahead with its foray into specialty products as one of its strategies to create a pool of niche products.

The company in a statement yesterday said that it had recently obtained registration approval and launched Erysaa, an Erythropoeitin (EPO) product. EPO is the protein present in the human body that adjusts the red blood cell generation in accordance with the oxygen requirement of the human body.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma , niche , products , EPO , profit ,

   

Next In Business News

Feytech signs underwriting agreement for listing on Main Market
EPF Account 3 draws concerns over dividends
Developers gearing up for higher sales
Kimlun wins RM150mil deal from Astaka
Systech gets shareholders’ nod for capital exercise
Huawei starts new smartphone Pura 70 sale amid scrutiny on chips
Smart Asia en route for listing on ACE Market
IGB-REIT likely to maintain organic growth
State-owned enterprises achieve milestone in key HSR construction
Trading suspension for Awanbiru

Others Also Read